A nanomedicine based combination therapy based on QLPVM peptide   functionalized liposomal tamoxifen and doxorubicin against Luminal A   breast cancer

doi:10.1016/j.nano.2015.12.360

CORC > 北京大学 > 工学院

	A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer
	Wang, Xiaoyou ; Chen, Xianhui ; Yang, Xiucong ; Gao, Wei ; He, Bing ; Dai, Wenbing ; Zhang, Hua ; Wang, Xueqing ; Wang, Jiancheng ; Zhang, Xuan ; Dai, Zhifei ; Zhang, Qiang
刊名	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
	2016
关键词	Nanomedicine based combinational therapy Penta-peptide QLPVM Luminal A breast cancer Tamoxifen Doxorubicin CELL-PENETRATING PEPTIDES DELIVERY TUMORS NANOPARTICLES EFFICACY SUBTYPES RELEASE BIOLOGY KU70
DOI	10.1016/j.nano.2015.12.360
英文摘要	Though combination chemotherapy or antitumor nanomedicine is extensively investigated, their combining remains in infancy. Additionally, enhanced delivery of estrogen or its analogs to tumor with highly-expressed estrogen-receptor (ER) is seldom considered, despite its necessity for ER-positive breast cancer treatment. Here, nanomedicine based combination therapy using QLPVM conjugated liposomal tamoxifen (TAM) and doxorubicin (DOX) was designed and testified, where the penta-peptide was derived from Ku70 Baxbinding domain. Quantitative, semi-quantitative and qualitative approaches demonstrated the enhanced endocytosis and cytotoxicity of QLPVM conjugated sterically stabilized liposomes (QLPVM-SSLs) in vitro and in vivo. Mechanism studies of QLPVM excluded the possible electrostatic, hydrophobic or receptor-ligand interactions. However, as a weak cell-penetrating peptide, QLPVM significantly induced drug release from QLPVM-SSLs during their interaction with cells, which was favorable for drug internalization. These findings suggested that the nanomedicine based combination therapy using QLPVM-SSL-TAM and QLPVM-SSL-DOX might provide a rational strategy for Luminal A breast cancer. From the Clinical Editor: Breast cancer remains a leading cause of mortality in women worldwide. Although combined therapy using hormonal antagonist and chemotherapy is the norm nowadays, the use of these agents together in a single delivery system has not been tested. Here, the authors investigated this approach using QLPVM conjugated liposomes in in-vitro and in-vivo models. The positive findings may provide a novel direction for breast cancer treatment in the near future. (c) 2015 Elsevier Inc. All rights reserved.; SCI(E); EI; PubMed; ARTICLE; zqdodo@bjmu.edu.cn; 2; 387-397; 12
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/435608]
专题	工学院
推荐引用方式 GB/T 7714	Wang, Xiaoyou,Chen, Xianhui,Yang, Xiucong,et al. A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer[J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE,2016.
APA	Wang, Xiaoyou.,Chen, Xianhui.,Yang, Xiucong.,Gao, Wei.,He, Bing.,...&Zhang, Qiang.(2016).A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer.NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE.
MLA	Wang, Xiaoyou,et al."A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer".NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016).